Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of
VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing
surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be
enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by
protocol amendment if deemed necessary by the DSC to meet primary and/or secondary
objectives.